Autopsy report · NCT00090129

Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis

“The risk-benefit ratio for the use of onercept in this condition was not sufficiently favorable to justify continued development”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 854 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

EMD Serono

Sponsor type

Industry

Conditions

Arthritis, Psoriatic

Interventions

Onercept; Placebo

Participants

854

Sites

40

Countries

Canada, United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.